The potential of programmed death ligand-1 expression in ovarian malignant germ cell tumors as a prognostic factor

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394-424. DOI: 10.3322/caac.2149210.3322/caac.2149230207593Search in Google Scholar

2. Cancer Registration Agency Indonesian Association of Pathologists, Cancer in Indonesia 2013: histopathologic data. Jakarta: Cancer Registration Agency; 2017.Search in Google Scholar

3. Alifrangis C, Seck MJ. Malignant ovarian germ cell tumours: an overview of management and controversies. In: Lauraine EP, Coquard IR, Lécuru F, editors. Ovarian cancers: advances through international research cooperation (gineco, engot, gcig). 1st ed. Switzerland: Springer; 2017. p.247-59. DOI: 10.1007/978-3-319-32110-3_1810.1007/978-3-319-32110-3_18Search in Google Scholar

4. Kempf E, Desamericq G, Vieites B, Diaz-Padilla I, Calvo E, Estevez P, et al. Clinical and pathologic features of patients with non-epithelial ovarian cancer: retrospective analysis of a single institution 15-year experience. Clin Transl Oncol. 2017 Feb 1;19(2):173-9. DOI: 10.1007/s12094-016-1517-x10.1007/s12094-016-1517-x27193130Search in Google Scholar

5. Kohli M, Zhang BY, Costello BA. Management of germ cell tumors. In: Nogales FF, Jimenez RE, editors. Pathology and biology of human germ cell tumors. Berlin: Springer; 2017. p.181-94. DOI: 10.1007/978-3-662-53775-6_510.1007/978-3-662-53775-6_5Search in Google Scholar

6. Chovanec M, Cierna Z, Miskovska V, Machalekova K, Svetlovska D, Kalavska K, et al. Prognostic role of programmed-death ligand 1 (PD-L1) expressing tumor infiltrating lymphocytes in testicular germ cell tumors. Oncotarget. 2017 Mar 28;8(13):21794-805. DOI: 10.18632/oncotarget.1558510.18632/oncotarget.15585540062428423520Search in Google Scholar

7. Drakes ML, Mehrotra S, Aldulescu M, Potkul RK, Liu Y, Grisoli A, et al. Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand-1 (PD-L1) in ovarian cancer. J Ovarian Res. 2018 May 30;11(1):43. DOI: 10.1186/s13048-018-0414-z10.1186/s13048-018-0414-z597552429843813Search in Google Scholar

8. Darb-Esfahani S, Kunze CA, Kulbe H, Sehouli J, Wienert S, Lindner J, et al. Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PDL1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma. Oncotarget. 2016 Jan 12;7(2):1486-99. DOI: 10.18632/oncotarget.642910.18632/oncotarget.6429481147526625204Search in Google Scholar

9. Cierna Z, Mego M, Miskovska V, Machalekova K, Chovanec M, Svetlovska D, et al. Prognostic value of programmed-death-1 receptor (PD-1) and its ligand 1 (PD-L1) in testicular germ cell tumors. Ann Oncol. 2016 Feb;27(2):300-5. DOI: 10.1093/annonc/mdv57410.1093/annonc/mdv574475122226598537Search in Google Scholar

10. Fankhauser CD, Curioni-Fontecedro A, Allman V, Beyer J, Tischler V, Sulser T, et al. Frequent PD-L1 expression in testicular germ cell tumors. Br J Cancer. 2015 Jul 28;113(3):411-3. DOI: 10.1038/bjc.2015.24410.1038/bjc.2015.244452264226171934Search in Google Scholar

11. Guan J, Lim KS, Mekhail T, Chang CC, Programmed death ligand-1 (PD-L1) expression in the programmed death receptor-1 (PD-1)/PD-L1 blockade: a key player against various cancers. Arch Pathol Lab Med. 2017 Jun;141(6):851-61. DOI: 10.5858/arpa.2016-0361-RA10.5858/arpa.2016-0361-RA28418281Search in Google Scholar

12. Zhu J, Wen H, Bi R, Wu Y, Wu X. Prognostic value of programmed death-ligand 1 (PD-L1) expression in ovarian clear cell carcinoma. J Gynecol Oncol. 2017 Nov;28(6):e77. DOI: 10.3802/jgo.2017.28.e7710.3802/jgo.2017.28.e77564152729027395Search in Google Scholar

13. Cheng X, Dai H, Wan N, Moore Y, Vankayalapati R, Dai Z. Interaction of programmed death-1 and programmed death-1 ligand-1 contributes to testicular immune privilege. Transplantation. 2009 Jun 27;87(12):1778-86. DOI: 10.1097/TP.0b013e3181a7563310.1097/TP.0b013e3181a7563319543053Search in Google Scholar

14. Sever M, Jones TD, Roth LM, Karim FW, Zheng W, Michael H, et al. Expression of CD117 (c-kit) receptor in dysgerminoma of the ovary: diagnostic and therapeutic implications. Mod Pathol. 2005 Nov;18(11):1411-6. DOI: 10.1038/modpathol.380046310.1038/modpathol.380046316056250Search in Google Scholar

15. Newbould MJ. Germ cell tumors of the ovary and dys-genetic gonads. In: Wilkinson N, editor. Essentials of diagnostic gynocological pathology: pathology of the ovary, fallopian tube and peritoneum. London: Springer; 2014. p.289-326. DOI: 10.1007/978-1-4471-2942-4_1410.1007/978-1-4471-2942-4_14Search in Google Scholar

16. Medeiros F, Crum CP. Germ cell tumors of the ovary. In: Crum CP, Nucci MR, Lee KR, editors. Diagnostic gynecologic and obstetric pathology. 2nd ed. Philadelphia: Elsevier saunders; 2011. p.904-37. DOI: 10.1016/B978-1-4377-0764-9.00029-910.1016/B978-1-4377-0764-9.00029-9Search in Google Scholar

17. Zaloudek CJ. Pathology of germ cell tumors. In: Soslow RA, Tornos C, editors. Diagnostic pathology of ovarian tumors. New York: Springer; 2011. p.155-91. DOI: 10.1007/978-1-4419-9751-7_1310.1007/978-1-4419-9751-7_13Search in Google Scholar

18. Davick JJ, Frierson HF, Smolkin M, Gru AA. PD-L1 expression in tumor cells and the immunologic milieu of bladder carcinomas: a pathologic review of 165 cases. Hum Pathol. 2018 Nov;81:184-91. DOI: 10.1016/j. humpath.2018.06.028Search in Google Scholar

19. Shi SJ, Wang LJ, Wang GD, Guo ZY, Wei M, Meng YL, et al. B7-H1 expression is associated with poor prognosis in colorectal carcinoma and regulates the proliferation and invasion of HCT116 colorectal cancer cells. PloS one. 2013 Oct 4;8(10):e76012. DOI: 10.1371/journal.pone.007601210.1371/journal.pone.0076012379081924124529Search in Google Scholar

20. Scheel AH, Ansén S, Schultheis AM, Scheffler M, Fischer RN, Michels S, et al. PD-L1 expression in non-small cell lung cancer: correlations with genetic alterations. Oncoimmunology. 2016 Mar 16;5(5):e1131379. DOI: 10.1080/2162402X.2015.113137910.1080/2162402X.2015.1131379491069827467949Search in Google Scholar

21. Li J, Wang P, Xu Y. Prognostic value of programmed cell death-ligand 1 expression in patients with head and neck cancers: a systematic review dan meta-analysis. PloS One. 2017 Jun 12;12(6):e0179536. DOI: 10.1371/journal.pone.017953610.1371/journal.pone.0179536546785328604812Search in Google Scholar

22. Guo Y, Yu P, Liu Z, Maimaiti Y, Wang S, Yin X, et al. Prognostic and clinicopathological value of programmed death ligand-1 in breast cancer: a meta-analysis. PloS one. 2016 May 26;11(5):e0156323. DOI: 10.1371/journal.pone.015632310.1371/journal.pone.0156323488202327227453Search in Google Scholar

23. Parra ER, Villalobos P, Mino B, Rodriguez-Canales J. Comparison of different antibody clones for immunohistochemistry detection of programmed cell death ligand 1 (PD-L1) on non-small cell lung carcinoma. Appl Immunohistochem Mol Morphol. 2018 Feb;26(2):83-93. DOI: 10.1097/PAI.000000000000053110.1097/PAI.0000000000000531581563528719380Search in Google Scholar

24. Hendry S, Byrne DJ, Wright GM, Young RJ, Stur-rock S, Cooper WA, et al. Comparison of four PD-L1 immunohistochemical assays in lung cancer. J Thorac Oncol. 2018 Mar;13(3):367-76. DOI: 10.1016/j. jtho.2017.11.112Search in Google Scholar

25. Zhu J, Wen H, Ju X, Bi R, Zuo W, Wu X. Clinical significance of programmed death ligand-1 and intra-tumoral CD8+ T lymphocytes in ovarian carcinosarcoma. PloS one. 2017 Jan 26;12(1):e0170879. DOI: 10.1371/journal.pone.017087910.1371/journal.pone.0170879526865528125702Search in Google Scholar